Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a cancer linked to the Epstein-Barr virus (EBV), such as nasopharyngeal cancer (a type of cancer in the back of the nose and throat).
- People who have been diagnosed with a cancer linked to the human papillomavirus (HPV), including certain squamous cell cancers of the head and neck, cervix, vulva, or anal canal. For head and neck cancers, a positive HPV test (or a related test called p16) is required; this is not required for cervical, vulvar, or anal canal cancers.
- People with anal canal cancer where late-stage tumour tissue is preferred for the study, though early-stage tissue may be acceptable in some cases (confirm with trial site).
- People with liver cancer (hepatocellular carcinoma, or HCC) who have above-normal levels of a protein called alpha-fetoprotein (AFP) in their blood, as measured by the hospital's standard reference range.
- People who are 18 years of age or older.
- People who have given their voluntary written agreement to take part in the trial.
Who may not be able to join:
- People with any condition that, in the opinion of the trial doctor, could affect their safety during the study or make it difficult to properly analyse the samples collected.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kathy Han, MD, Princess Margaret Cancer Centre
Phone: 416-946-4501
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Identifying the p-HLA epitopes across diverse HLA alleles
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.